XML 45 R36.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Entities - Theravance Respiratory Company, LLC (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Assets              
Cash and cash equivalents $ 283,580       $ 283,580   $ 201,525
Receivables from collaborative arrangements 111,676       111,676   110,711
Prepaid expenses 3,953       3,953   1,367
Equity and long-term investments 494,097       494,097   483,845
Total assets 1,137,639       1,137,639   926,395
Liabilities and LLC Members' Equity              
Current liabilities 125,908       125,908   5,807
Total liabilities and stockholders' equity 1,137,639       1,137,639   $ 926,395
Income statements              
Total revenue 108,220   $ 100,806   198,279 $ 186,324  
Operating expenses 25,666   4,266   37,996 10,301  
Income from operations 82,554   96,540   160,283 176,023  
Other income, net (528)   (951)   (778) (1,384)  
Income tax expense (benefit), net (876)   25,333   5,984 45,069  
Changes in fair values of equity and long-term investments (58,600)   45,315   (68,011) 100,360  
Net income 21,371 $ 37,858 110,846 $ 109,695 $ 59,229 220,541  
Theravance Respiratory Company, LLC              
CONSOLIDATED ENTITIES              
Economic interest in LLC (in percent)         15.00%   15.00%
Assets              
Cash and cash equivalents 89,806       $ 89,806   $ 50,713
Receivables from collaborative arrangements 42,720       42,720   42,492
Prepaid expenses 85       85   71
Equity and long-term investments 42,536       42,536   37,695
Total assets 175,147       175,147   130,971
Liabilities and LLC Members' Equity              
Current liabilities 493       493   252
LLC members' equity 174,654       174,654   130,719
Total liabilities and stockholders' equity 175,147       175,147   $ 130,971
Income statements              
Operating expenses 139   336   337 3,617  
Income from operations 42,581   26,050   71,692 44,853  
Other income, net 10   0   10 0  
Income tax expense (benefit), net 0   0   1 0  
Changes in fair values of equity and long-term investments (9,313)   (254)   (8,884) (737)  
Net income 33,278   25,796   62,819 44,116  
Theravance Respiratory Company, LLC | Royalty revenue from a related party              
Income statements              
Total revenue $ 42,720   $ 26,386   $ 72,029 $ 48,470